27723749|t|SF2312 is a natural phosphonate inhibitor of enolase
27723749|a|Despite being crucial for energy generation in most forms of life, few if any microbial antibiotics specifically inhibit glycolysis. To develop a specific inhibitor of the glycolytic enzyme enolase 2 (ENO2) for the treatment of cancers with deletion of ENO1 (encoding enolase 1), we modeled the synthetic tool compound inhibitor phosphonoacetohydroxamate (PhAH) into the active site of human ENO2. A ring-stabilized analog of PhAH, in which the hydroxamic nitrogen is linked to Cα by an ethylene bridge, was predicted to increase binding affinity by stabilizing the inhibitor in a bound conformation. Unexpectedly, a structure-based search revealed that our hypothesized backbone-stabilized PhAH bears strong similarity to SF2312, a phosphonate antibiotic of unknown mode of action produced by the actinomycete Micromonospora, which is active under anaerobic conditions. Here, we present multiple lines of evidence, including a novel X-ray structure, that SF2312 is a highly potent, low - nanomolar inhibitor of enolase.
27723749	0	6	SF2312	T195	C0003232
27723749	12	19	natural	T169	C0205296
27723749	20	31	phosphonate	T109	C0260127
27723749	32	41	inhibitor	T080	C1999216
27723749	45	52	enolase	T116,T126	C0031691
27723749	79	96	energy generation	T044	C2263100
27723749	114	118	life	T078	C0376558
27723749	131	140	microbial	T001	C0599840
27723749	141	152	antibiotics	T195	C0003232
27723749	166	173	inhibit	T052	C3463820
27723749	174	184	glycolysis	T044	C0017952
27723749	199	207	specific	T080	C0205369
27723749	208	217	inhibitor	T080	C1999216
27723749	225	235	glycolytic	T044	C0017952
27723749	236	252	enzyme enolase 2	T059	C0202144
27723749	254	258	ENO2	T059	C0202144
27723749	268	277	treatment	T169	C1522326
27723749	281	288	cancers	T191	C0006826
27723749	294	302	deletion	T045	C0017260
27723749	306	310	ENO1	T028	C1414402
27723749	321	330	enolase 1	T116,T126	C2364020
27723749	363	371	compound	T080	C0205198
27723749	372	381	inhibitor	T080	C1999216
27723749	382	407	phosphonoacetohydroxamate	T109	C0255101
27723749	409	413	PhAH	T109	C0255101
27723749	424	435	active site	T169	C0205681
27723749	439	444	human	T016	C0086418
27723749	445	449	ENO2	T059	C0202144
27723749	453	475	ring-stabilized analog	T104	C0243071
27723749	479	483	PhAH	T109	C0255101
27723749	498	555	hydroxamic nitrogen is linked to Cα by an ethylene bridge	T104	C1254350
27723749	561	570	predicted	T078	C0681842
27723749	574	582	increase	T169	C0442805
27723749	583	590	binding	T052	C1145667
27723749	591	599	affinity	T070	C1510827
27723749	603	614	stabilizing	T033	C0184512
27723749	619	628	inhibitor	T080	C1999216
27723749	634	652	bound conformation	T082	C0026377
27723749	670	685	structure-based	T104	C1254350
27723749	686	692	search	T052	C1706202
27723749	693	701	revealed	T080	C0443289
27723749	724	743	backbone-stabilized	T033	C0184512
27723749	744	748	PhAH	T109	C0255101
27723749	755	761	strong	T080	C0442821
27723749	762	772	similarity	T080	C2348205
27723749	776	782	SF2312	T195	C0003232
27723749	786	797	phosphonate	T109	C0260127
27723749	798	808	antibiotic	T195	C0003232
27723749	812	819	unknown	T080	C0439673
27723749	820	834	mode of action	T169	C1524059
27723749	851	863	actinomycete	T007	C0600148
27723749	864	878	Micromonospora	T007	C0025996
27723749	889	895	active	T169	C0205177
27723749	902	911	anaerobic	T080	C3641081
27723749	912	922	conditions	T080	C0348080
27723749	959	967	evidence	T078	C3887511
27723749	969	978	including	T169	C0332257
27723749	981	986	novel	T080	C0205314
27723749	987	992	X-ray	T059	C0206755
27723749	993	1002	structure	T104	C1254350
27723749	1009	1015	SF2312	T195	C0003232
27723749	1021	1027	highly	T080	C0205250
27723749	1028	1034	potent	T080	C0442821
27723749	1036	1039	low	T080	C0205251
27723749	1042	1051	nanomolar	T081	C0439282
27723749	1052	1061	inhibitor	T080	C1999216
27723749	1065	1072	enolase	T116,T126	C0031691